Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit

Molecular and Cellular Endocrinology

Volumn 384, Issue 1-2, 2014, Pages 143-154

  Vignozzi, Linda ^a   Filippi, Sandra ^b   Comeglio, Paolo ^a   Cellai, Ilaria ^a   Sarchielli, Erica ^a   Morelli, Annamaria ^a   Rastrelli, Giulia ^a   Maneschi, Elena ^a   Galli, Andrea ^a   Vannelli, Gabriella Barbara ^a   Saad, Farid ^c   Mannucci, Edoardo ^b   Adorini, Luciano ^d   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c BAYER PHARMA AG   (Germany)

^d INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

Hypogonadism; Infliximab; OCA; Testosterone; TNF

Indexed keywords

ACETYLCHOLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FARNESOID X RECEPTOR; INFLIXIMAB; OBETICHOLIC ACID; TESTOSTERONE ENANTATE; TUMOR NECROSIS FACTOR ALPHA; VARDENAFIL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; ERECTILE DYSFUNCTION; EXPERIMENTAL STUDY; FIBROSIS; GENE EXPRESSION; HISTOPATHOLOGY; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RABBIT; STELLATE CELL;

HYPOGONADISM; INFLIXIMAB; OCA; TESTOSTERONE; TNFΑ;

ACETYLCHOLINE; ANIMALS; ANTIBODIES, MONOCLONAL; CHENODEOXYCHOLIC ACID; DIET, HIGH-FAT; DIETARY FATS; ERECTILE DYSFUNCTION; FATTY LIVER; GENE EXPRESSION; HUMANS; IMIDAZOLES; LIVER; MALE; METABOLIC SYNDROME X; PENIS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; RABBITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONES; TESTOSTERONE; TRIAZINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896738769     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.01.014     Document Type: Article

References (46)

1. Adorini L., Pruzanski M., Shapiro D., Farnesoid X. Receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 2012, 17:988-997.
2. Alkhouri N., Tamimi T.A., Yerian L., Lopez R., Zein NN., Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig. Dis. Sci. 2010, 55:2644-2650.
3. Anderson H.D., Rahmutula D. Gardner DG Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J. Biol. Chem. 2004, 279:963-969.
4. Araña Rosaínz Mde J., Ojeda MO., Acosta JR., Elías-Calles LC., González NO., Herrera OT., et al. Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction. J. Sex Med. 2011, 8:2017-2030.
5. Burra P., Germani G., Masier A., De Martin E., Gambato M., Salonia A., et al. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure?. Transplantation 2010, 89:1425-1429.
6. Carneiro F.S., Sturgis L.C., Giachini F.R., Carneiro Z.N., Lima V.V., Wynne B.M., et al. TNF-alpha knockout mice have increased corpora cavernosa relaxation. J. Sex Med. 2009, 6:115-125.
7. Carneiro F.S., Webb R.C., Tostes R.C. Emerging role for TNF-α in erectile dysfunction. J. Sex Med. 2010, 7:3823-3834.
8. Chia S., Qadan M., Newton R., Ludlam C.A., Fox K.A. Newby DE Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler. Thromb. Vasc. Biol. 2003, 23:695-701.
9. Corona G., Mannucci E., Schulman C., Petrone L., Mansani R., Cilotti A., et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur. Urol. 2006, 50:595-604.
10. Corona G., Rastrelli G., Morelli A., Vignozzi L., Mannucci E., Maggi M. Hypogonadism and metabolic syndrome. J. Endocrinol. Invest. 2011, 34:557-567.
11. Corona G., Rastrelli G., Vignozzi L., Mannucci E., Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25:337-353.
12. Dowman J.K., Hopkins L.J., Reynolds G.M., Armstrong M.J., Nasiri M., Nikolaou N., et al. Loss of 5α-reductase Type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology 2013, 154(12):4536-4547.
13. Filippi S., Vignozzi L., Morelli A., Chavalmane A.K., Sarchielli E., Fibbi B., et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J. Sex Med. 2009, 6:3274-3288.
14. Haider A., Gooren L.J., Padungtod P., Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp. Clin. Endocrinol. Diabetes 2010, 118:167-1671.
15. Hayward M.D., Jones B.K., Saparov A., Hain H.S., Trillat A.C., Bunzel M.M., et al. An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol. 2007, 10:7-13.
16. Hoyos C.M., Yee B.J., Phillips C.L., Machan E.A., Grunstein R.R., Liu P.Y. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnea: a randomized placebo-controlled trial. Eur. J. Endocrinol. 2012, 167:531-541.
17. Kalinchenko S.Y., Tishova Y.A., Mskhalaya G.J., Gooren L.J., Giltay E.J., Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin. Endocrinol. 2010, 73:602-612.
18. Kim S., Kwon H., Park J.H., Cho B., Kim D., Oh S.W., et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012, 12:69-73.
19. Li Y., Liu L., Wang B., Wang J., Chen D. Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. Clin. Res. Hepatol. Gastroenterol. 2013, pii:S2210-7401(13)00180-0.10.1016/j.clinre.2013.08.006.
20. Lin H.Y., Yu I.C., Wang R.S., Chen Y.T., Liu N.C., Altuwaijri S., et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 2008, 47:1924-1935.
21. Long T., Liu G., Wang Y., Chen Y., Zhang Y., Qin D. TNF-α, erectile dysfunction, and NADPH oxidase-mediated ROS generation in corpus cavernosum in high-fat diet/streptozotocin-induced diabetic rats. J. Sex Med. 2012, 9:1801-1814.
22. Maneschi E., Morelli A., Filippi S., Cellai I., Comeglio P., Mazzanti B., et al. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J. Endocrinol. 2012, 215:347-362.
23. Maneschi E., Vignozzi L., Morelli A., Mello T., Filippi S., Cellai I., et al. FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J. Endocrinol. 2013, 218:215-231.
24. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
25. Matos G., Hirotsu C., Alvarenga T.A., Cintra F., Bittencourt L., Tufik S., et al. The association between TNF-α and erectile dysfunction complaints. Andrology 2013, 1:872-878.
26. Morelli A., Filippi S., Mancina R., Luconi M., Vignozzi L., Marini M., Orlando C., Vannelli G.B., Aversa A., Natali A., Forti G., Giorgi M., Jannini E.A., Ledda F., Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004, 145:2253-2263.
27. Morelli A., Comeglio P., Filippi S., Sarchielli E., Vignozzi L., Maneschi E., Cellai I., Gacci M., Lenzi A., Vannelli G.B., Maggi M. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate 2013, 73:428-441.
28. Mudaliar S., Henry R.R., Sanyal A.J., Morrow L., Marschall H.U., Kipnes M., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013, 145:574-582.
29. Ogawa T., Fujii H., Yoshizato K., Kawada N. A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am. J. Pathol. 2010, 177:153-165.
30. Ryffel B., Mihatsch M.J. TNF receptor distribution in human tissues. Int. Rev. Exp. Pathol. 1993, 34:149-156.
31. Targher G., Day C.P. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. Hepatology 2011, 53:375-386.
32. Targher G., Bertolini L., Rodella S., Lippi G., Franchini M., Zoppini G., et al. Day CP NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 2008, 16:1394-1399.
33. Tilg H., Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000, 343:1467-1476.
34. Traish A.M., Feeley R.J., Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS J. 2009, 276:5755-5767.
35. Traish A.M., Miner M.M., Morgentaler A., Zitzmann M. Testosterone deficiency. Am. J. Med. 2011, 124:578-587.
36. Traish A.M., Haider A., Doros G., Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int. J. Clin. Pract. 2013, 10.1111/ijcp.12319.
37. Vignozzi L., Corona G., Petrone L., Filippi S., Morelli A.M., Forti G., Maggi M. Testosterone and sexual activity. J. Endocrinol. Invest. 2005, 28:39-44.
38. Vignozzi L., Morelli A., Filippi S., Comeglio P., Chavalmane A.K., Marchetta M., et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J. Sex Med. 2011, 8:57-77.
39. Vignozzi L., Morelli A., Sarchielli E., Comeglio P., Filippi S., Cellai I., et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J. Endocrinol. 2012, 212:71-84.
40. Vignozzi L., Filippi S., Morelli A., Comeglio P., Cellai I., Sarchielli E., et al. Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors. J. Sex Med. 2012, 9:3028-3040.
41. Vignozzi L., Cellai I., Santi R., Lombardelli L., Morelli A., Comeglio P., et al. Anti-inflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J. Endocrinol. 2012, 211:31-43.
42. Vignozzi L., Gacci M., Cellai I., Santi R., Corona G., Morelli A., Rastrelli G., et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013, 73:789-800.
43. Vlachopoulos C., Aznaouridis K., Ioakeimidis N., Rokkas K., Vasiliadou C., Alexopoulos N., et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur. Heart J. 2006, 27:2640-2648.
44. Völzke H., Aumann N., Krebs A., et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int. J. Androl. 2010, 33:45-53.
45. Yoshizumi M., Perrella M.A., Burnett J.C., Lee M.E. Tumor necrosis factor down-regulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 1993, 73:205-209.
46. Zhang L., Connelly J.J., Peppel K., Brian L., Shah S.H., Nelson S., et al. Aging-related atherosclerosis is exacerbated by arterial expression of tumor necrosis factor receptor-1: evidence from mouse models and human association studies. Hum. Mol. Genet. 2010, 19:2754-2766.